

TIDOMET PLUS

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
Abbreviated Prescribing information for TIDOMET PLUS (Levodopa 100 mg and Carbidopa 25mg Tablets) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Levodopa is a precursor of dopamine, and is given as replacement therapy in Parkinson's disease. Carbidopa is a peripheral dopa decarboxylase inhibitor. **INDICATION:** Indicated for the treatment of the parkinson's disease. **DOSAGE AND ADMINISTRATION:** Carbidopa/levodopa combination tablets are available in a ratio of 1:4 or 1:10 of carbidopa to levodopa to provide facility for fine dosage titration for each patient. One tablet of Carbidopa/levodopa combination 25 mg/100 mg three times a day. **CONTRAINDICATIONS:** Contraindicated with Nonselective monoamine oxidase (MAO) inhibitors, narrow-angle glaucoma, in patients with suspicious undiagnosed skin lesions or a history of melanoma and in patients with known hypersensitivity to any component of this medication and in patients with severe psychoses. **WARNINGS & PRECAUTIONS:** dyskinesias (involuntary movements), suicidal tendencies, patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. gastrointestinal hemorrhage in patients with a history of peptic ulcer, Neuroleptic Malignant Syndrome, Hyperpyrexia and Confusion, Impulse Control/Compulsive Behaviors, Hallucinations/Psychotic-Like Behavior, Depression, Melanoma. **DRUG INTERACTIONS:** With antihypertensive drugs: postural hypotension may occur; with selegiline: severe orthostatic hypotension; with tricyclic antidepressants: hypertension and dyskinesia. Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. Iron salts may reduce the bioavailability of levodopa and carbidopa. Metoclopramide may increase the bioavailability of levodopa. **ADVERSE REACTIONS:** Dyskinesias, such as choreiform, dystonic and other involuntary movements and nausea, chest pain, asthenia, cardiac irregularities, hypotension, hypertension, syncope, phlebitis, palpitation, gastrointestinal bleeding, development of duodenal ulcer, anorexia, vomiting, diarrhea, constipation, dyspepsia, dry mouth, taste alterations, thrombocytopenia, leukopenia, angioedema, urticaria, pruritus, back pain, shoulder pain, muscle cramps, Psychotic episodes including delusions, hallucinations and paranoid ideation, neuroleptic malignant syndrome (NMS), confusion, agitation, dizziness, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, dyspnea, upper respiratory infection, rash, increased sweating, alopecia, urinary tract infection, urinary frequency, weight gain, weight loss, cough, diplopia, blurred vision, faintness, hoarseness, malaise.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/ TIDOMET PLUS 100,25mg /Feb-15/01/AbPI
(Additional information is available on request)